CliffBio
biologic

Ultomiris

ravulizumab-cwvz

Loss of exclusivityJune 2034projected — 12-year biologic exclusivity estimate
CompanyAlexion Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameUltomiris
Active ingredientravulizumab-cwvz
Strength245MG/3.5ML (70MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2022
Marketing statusRx

More from Alexion Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Ultomiris patent cliff — loss of exclusivity June 2034 | CliffBio